EMCrit 258 – Should Andexxa be added to a Hospital’s Formulary? - a podcast by Scott D. Weingart, MD FCCM

The question of the use of Andexxa, a reversal agent for Factor Xa Inhibitors, has been batting around my brain for a few months now. We are in the unfortunate position of having a drug with very questionable evidentiary support but with an FDA labelled indication. I received an email from the lead author of paper just published in Neurocritical Care.



* Peled et al. Key Points to Consider When Evaluating Andexxa for Formulary Addition. Neurocrit Care 10.1007/s12028-019-00866-6



Dr. Harry Peled is the medical director of Cardiology and Critical Care at St Jude Medical Center in California. Relevantly, he is also chair of the Pharmacy an Therapeutics Committee.



I would love to hear your thoughts on this issue--place them in the comments below.

See Also



* I Have Issues with Andexanet by K. Kipp, PharmD



Update:



* In-Vivo Trial of 4-Factor PCC for Reversal of Xas



Now on to the Podcast...

Further episodes of EMCrit Podcast

Further podcasts by Scott D. Weingart, MD FCCM

Website of Scott D. Weingart, MD FCCM